NO20003828L - 2,3,4,5-tetrahydro-1H- [1,4] benzodiazepine-3-hydroxamic acids as matrix metalloproteinase inhibitors - Google Patents
2,3,4,5-tetrahydro-1H- [1,4] benzodiazepine-3-hydroxamic acids as matrix metalloproteinase inhibitorsInfo
- Publication number
- NO20003828L NO20003828L NO20003828A NO20003828A NO20003828L NO 20003828 L NO20003828 L NO 20003828L NO 20003828 A NO20003828 A NO 20003828A NO 20003828 A NO20003828 A NO 20003828A NO 20003828 L NO20003828 L NO 20003828L
- Authority
- NO
- Norway
- Prior art keywords
- benzodiazepine
- tetrahydro
- matrix metalloproteinase
- metalloproteinase inhibitors
- hydroxamic acids
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Abstract
Forbindelser er tilveiebragt med formelen (I), HOHN hvori R, R,, RI, Ra og RA er definert i beskrivelsen, som har matriks- metalloproteinase inhiberende aktivitet.Compounds are provided of formula (I), HOHN wherein R, R 1, R 1, Ra and RA are defined in the specification which has matrix metalloproteinase inhibitory activity.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1437498A | 1998-01-27 | 1998-01-27 | |
PCT/US1999/001325 WO1999037625A1 (en) | 1998-01-27 | 1999-01-22 | 2,3,4,5-tetrahydro-1h-[1,4]-benzodiazepine-3-hydroxamic acids as matrix metalloproteinase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20003828D0 NO20003828D0 (en) | 2000-07-26 |
NO20003828L true NO20003828L (en) | 2000-09-26 |
Family
ID=21765097
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20003828A NO20003828L (en) | 1998-01-27 | 2000-07-26 | 2,3,4,5-tetrahydro-1H- [1,4] benzodiazepine-3-hydroxamic acids as matrix metalloproteinase inhibitors |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP1051407A1 (en) |
JP (1) | JP2002501056A (en) |
KR (1) | KR20010034406A (en) |
CN (1) | CN1293663A (en) |
AR (1) | AR017230A1 (en) |
AU (1) | AU2240299A (en) |
BR (1) | BR9907746A (en) |
CA (1) | CA2317546A1 (en) |
HU (1) | HUP0100277A3 (en) |
IL (1) | IL137162A0 (en) |
NO (1) | NO20003828L (en) |
PL (1) | PL342045A1 (en) |
WO (1) | WO1999037625A1 (en) |
ZA (1) | ZA99569B (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6458783B1 (en) * | 1997-09-29 | 2002-10-01 | Bristol-Myers Squibb Company | Non-imidazole benzodiazepine inhibitors of farnesyl protein transferase |
AR022423A1 (en) * | 1999-01-27 | 2002-09-04 | American Cyanamid Co | COMPOUNDS DERIVED FROM ACIDS 2,3,4,5-TETRAHIDRO-1H- [1,4] BENZODIAZEPINA-3-HYDROXAMICS, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM, AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINAL PRODUCT |
US6544984B1 (en) | 1999-01-27 | 2003-04-08 | American Cyanamid Company | 2,3,4,5-tetrahydro-1H-(1,4)benzodiazepine-3-hydroxamic acids |
US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
US20030051728A1 (en) | 2001-06-05 | 2003-03-20 | Lloyd Peter M. | Method and device for delivering a physiologically active compound |
US20070122353A1 (en) | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
CA2451955C (en) | 2001-06-26 | 2015-09-29 | Abgenix, Inc. | Antibodies to opgl |
US20080216828A1 (en) | 2007-03-09 | 2008-09-11 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
FR2950057B1 (en) | 2009-09-17 | 2011-08-26 | Galderma Res & Dev | NOVEL BENZENE CARBOXYLAMIDE COMPOUNDS, PROCESS FOR THEIR SYNTHESIS AND THEIR USE IN MEDICINE AND COSMETICS |
FR2950056B1 (en) | 2009-09-17 | 2011-08-26 | Galderma Res & Dev | NOVEL BENZENE CARBOXYLAMIDE COMPOUNDS, PROCESS FOR THEIR SYNTHESIS AND THEIR USE IN MEDICINE AND COSMETICS |
BR112021006407A8 (en) | 2018-10-04 | 2022-12-06 | Inst Nat Sante Rech Med | use of egfr inhibitors for keratoderms |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0861236T4 (en) * | 1995-11-13 | 2006-12-18 | Sanofi Aventis Deutschland | Cyclic and heterocyclic N-substituted alpha-amino hydroxamic and carboxylic acids |
US6153757A (en) * | 1995-12-08 | 2000-11-28 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors and intermediates useful for their preparation |
-
1999
- 1999-01-22 BR BR9907746-9A patent/BR9907746A/en not_active Application Discontinuation
- 1999-01-22 WO PCT/US1999/001325 patent/WO1999037625A1/en not_active Application Discontinuation
- 1999-01-22 JP JP2000528549A patent/JP2002501056A/en active Pending
- 1999-01-22 HU HU0100277A patent/HUP0100277A3/en unknown
- 1999-01-22 CN CN99804237A patent/CN1293663A/en active Pending
- 1999-01-22 EP EP99902417A patent/EP1051407A1/en not_active Withdrawn
- 1999-01-22 CA CA002317546A patent/CA2317546A1/en not_active Abandoned
- 1999-01-22 AU AU22402/99A patent/AU2240299A/en not_active Abandoned
- 1999-01-22 IL IL13716299A patent/IL137162A0/en unknown
- 1999-01-22 PL PL99342045A patent/PL342045A1/en unknown
- 1999-01-22 KR KR1020007008171A patent/KR20010034406A/en not_active Application Discontinuation
- 1999-01-26 ZA ZA9900569A patent/ZA99569B/en unknown
- 1999-01-26 AR ARP990100299A patent/AR017230A1/en unknown
-
2000
- 2000-07-26 NO NO20003828A patent/NO20003828L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO20003828D0 (en) | 2000-07-26 |
IL137162A0 (en) | 2001-07-24 |
CA2317546A1 (en) | 1999-07-29 |
BR9907746A (en) | 2000-10-17 |
AR017230A1 (en) | 2001-08-22 |
CN1293663A (en) | 2001-05-02 |
ZA99569B (en) | 2000-07-26 |
AU2240299A (en) | 1999-08-09 |
PL342045A1 (en) | 2001-05-21 |
EP1051407A1 (en) | 2000-11-15 |
HUP0100277A3 (en) | 2002-03-28 |
WO1999037625A1 (en) | 1999-07-29 |
HUP0100277A2 (en) | 2002-02-28 |
JP2002501056A (en) | 2002-01-15 |
KR20010034406A (en) | 2001-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO942064L (en) | inhibitors | |
NO992821L (en) | Ketobenzamides as Calpain Inhibitors | |
NO20005237L (en) | Heterocyclic substituted amides used as calpain inhibitors | |
DK0925303T3 (en) | Phosphinic acid amides as matrix metalloprotease inhibitors | |
TR200103493T2 (en) | Metalloprotease inhibitors | |
NO992492L (en) | Benzamidoaldehydes and their use as cysteine protease inhibitors | |
GB9801690D0 (en) | Therapeutic agents | |
NO972307D0 (en) | matrix metalloprotease inhibitors | |
NO990662L (en) | Thrombin inhibitors | |
FI942625A (en) | Peptide phosphinyloxymethyl ketones as inhibitors of interleukin-1beta-converting enzyme | |
AU4888401A (en) | Sulfonamide derivative as a matrix metalloproteinase inhibitor | |
NO20003828L (en) | 2,3,4,5-tetrahydro-1H- [1,4] benzodiazepine-3-hydroxamic acids as matrix metalloproteinase inhibitors | |
AU2003250475A1 (en) | 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors | |
NO20013675L (en) | 2,3,4,5-tetrahydro-1H- [1,4) benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors | |
NO991994L (en) | Substituted 4-biphenyl-4-hydroxy acid derivatives as matrix metalloprotease inhibitors | |
IL129035A0 (en) | 3-Mercaptoacetylamino-1,5-substituted-2-oxo- azepan derivatives useful as inhibitors of matrix metalloproteinase | |
BR0011801A (en) | Benzamide inhibitors replaced for rhinovirus 3c protease | |
DK1047665T3 (en) | Matrix metalloprotease inhibitors | |
DK1214302T3 (en) | Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones and their use as lipase inhibitors | |
DE69735479D1 (en) | METALOPROTEINASE INHIBITORS | |
ZA974033B (en) | Substituted 4-arylbutyric acid derivatives as matrix metalloprotease inhibitors. | |
NO20011654L (en) | Benzamide derivatives as thrombin inhibitors | |
BR9807920A (en) | Processes for treating dementia in a subject and for preventing dementia | |
DK0937075T3 (en) | New imidazo and oxazolopyridines as phosphodiesterase inhibitors | |
GB9723905D0 (en) | Heterocyclic compounds having MMP and TNF inhibitory activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |